Skip to main content
Jafron Biomedical Co.,Ltd. logo

Jafron Biomedical Co.,Ltd. — Investor Relations & Filings

Ticker · 300529 ISIN · CNE100002995 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,842 across all filing types
Latest filing 2018-10-09 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300529

About Jafron Biomedical Co.,Ltd.

https://www.jafron.com

Jafron Biomedical Co.,Ltd. specializes in the research, development, and manufacturing of biomaterials and equipment for blood purification. The company is a primary provider of hemoperfusion technology, focusing on the production of adsorbent cartridges designed to remove specific toxins and inflammatory mediators from the bloodstream. Its core product portfolio includes the HA series of hemoperfusion cartridges, which are applied in clinical settings for end-stage renal disease, acute poisoning, critical care, and liver failure. Beyond consumables, the company develops blood purification machines and integrated treatment systems. These solutions target clinical applications in nephrology, intensive care, and hepatology. By leveraging advanced resin adsorption technology, the company provides specialized extracorporeal blood treatment options aimed at improving patient outcomes in complex medical conditions.

Recent filings

Filing Released Lang Actions
关于拟变更公司经营范围的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding a proposed change in the company's business scope, including details of the current and proposed business activities. It mentions that the proposal was approved by the board and will be submitted to the shareholders for approval. There is no financial data, no mention of financial results, no audit information, no voting results, no executive changes, no legal proceedings, no merger or acquisition activity, and no report publication. The document is a regulatory announcement about corporate operational changes, specifically business scope modification, which fits best under Regulatory Filings (RNS) as it does not fit other more specific categories.
2018-10-09 Chinese
第三届监事会第十六次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolution passed at the 16th meeting of the third Supervisory Board of Zhuhai Jianfan Biotechnology Co., Ltd. It details the meeting attendance, the agenda item about establishing a holding subsidiary and related party transaction, and the voting results. It does not contain financial statements or detailed financial data, nor is it a report or presentation. It is an official announcement of a board/management decision related to corporate governance and internal approvals. Therefore, it fits best under Board/Management Information (MANG). The document length is short and it is not a report publication announcement or regulatory filing. Confidence is high due to clear meeting resolution content and voting results.
2018-10-09 Chinese
第三届董事会第二十三次会议决议公告
Board/Management Information Classification · 100% confidence The document is a formal announcement of resolutions passed at a board of directors meeting of Zhuhai Jianfan Biotechnology Co., Ltd. It details the meeting date, attendance, and voting results on various proposals such as establishing a subsidiary, changing company name, business scope, and amendments to the company charter. It also mentions that some proposals require shareholder approval. The document is short (1430 characters) and serves as a public disclosure of board decisions rather than a full report or detailed financial data. It fits the category of Board/Management Information (MANG) as it announces board meeting resolutions and management decisions.
2018-10-09 Chinese
关于召开2018年第二次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice about the convening of the 2018 second extraordinary general meeting of shareholders for Zhuhai Jianfan Biotechnology Co., Ltd. It includes information about the meeting date, voting procedures, agenda items (such as changes to company name, business scope, and articles of association), registration details, and proxy forms. There are no financial statements or financial performance data included. The document is an announcement informing shareholders about the meeting and how to participate and vote, rather than the actual results or minutes of the meeting. Therefore, it fits the category of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2018-10-09 Chinese
关于成立控股子公司暨关联交易的公告
Capital/Financing Update Classification · 95% confidence The document is a formal announcement by Zhuhai Jianfan Biotechnology Co., Ltd. regarding the establishment of a holding subsidiary and related party transactions. It details the investment overview, parties involved, shareholding structure, pricing policy, risks, and approvals by the board, independent directors, supervisory board, and sponsor institution. The document is an announcement of a corporate action (establishing a subsidiary and related party transaction) rather than a financial report or earnings release. It does not contain financial statements or quarterly/yearly results. It is not a regulatory filing or certification letter but a substantive announcement about corporate governance and investment activity. Therefore, the most appropriate classification is Capital/Financing Update (CAP), as it relates to company fundraising and capital structure changes through the establishment of a subsidiary and investment.
2018-10-09 Chinese
公司章程（2018年10月）
Governance Information Classification · 100% confidence The document is the Articles of Association (章程) of 珠海健帆生物科技股份有限公司, which is a detailed legal and organizational charter governing the company's structure, shareholder rights, board responsibilities, and meeting procedures. It references Chinese company law and securities law, and includes detailed provisions on shareholder meetings, voting rights, share issuance, and management roles. This type of document is a governance document that outlines the internal rules and governance practices of the company. It is not a financial report, audit report, earnings release, or any announcement related to capital changes or voting results. It is a comprehensive governance framework document. Therefore, the appropriate classification is Governance Information (CGR). The document length (15,000 characters) and content confirm it is the full governance charter, not a brief announcement or summary.
2018-10-09 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.